The role of innate immune signaling in regulation of tumor-associated myeloid cells

Inflammation and Immunity in Cancer

Volumn , Issue , 2015, Pages 25-47

  Shime, Hiroaki ^a   Matsumoto, Misako ^a   Seya, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Immune suppression; Innate immunity; Myeloid derived suppressor cells (Mdscs); Tlr; Tumor Associated macrophages (Tams)

Indexed keywords

EID: 84943376382     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55327-4_3     Document Type: Chapter

References (129)

1. Ahonen CL, Doxsee CL, McGurran SM et al (2004) Combined TLR and CD40 triggering induces potent CD8+T cell expansion with variable dependence on type I IFN. J Exp Med 199:775–784. doi: 10.1084/jem.20031591
2. Akazawa T, Ebihara T, Okuno M et al (2007) Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A 104:252–257. doi: 10.1073/pnas.0605978104
3. Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167:195–205. doi: 10.1111/j.1365-2249.2011.04515
4. Almand B, Clark JI, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689
5. Azuma M, Ebihara T, Oshiumi H et al (2012) Cross-priming for antitumor CTL induced by solubleAg + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. Oncoimmunology 1:581–592. doi: 10.4161/onci.19893
6. Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401–406. doi: 10.1038/clpt.2009.312
7. Biswas SKS, Mantovani AA (2010) Macrophage plasticity and interaction with lymphocyte subsets:cancer as a paradigm. Nat Immunol 11:889–896. doi: 10.1038/ni.1937
8. Blankenstein T, Qin ZH, Uberla K et al (1991) Tumor suppression after tumor-cell targeted tumornecrosis-factor-alpha gene-transfer. J Exp Med 173:1047–1052. doi: 10.1084/jem.173.5.1047
9. Blasius AL, Beutler B (2010) Intracellular toll-like receptors. Immunity 32:305–315. doi: 10.1016/j.immuni.2010.03.012
10. Chalmin F, Ladoire S, Mignot G et al (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120:457–471. doi: 10.1172/JCI40483
11. Charo IF (2007) Macrophage polarization and insulin resistance: PPARγ in control. Cell Metab 6:96–98. doi: 10.1016/j.cmet.2007.07.006
12. Cheng P, Corzo CA, Luetteke N et al (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J ExpMed 205:2235–2249. doi: 10.1084/jem.20080132
13. Condamine T, Gabrilovich DI (2011) Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32:19–25. doi: 10.1016/j.it.2010.10.002
14. Cortez-Retamozo V, Etzrodt M, Newton A et al (2012) Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 109:2491–2496. doi: 10.1073/pnas.1113744109
15. Corzo CA, Condamine T, Lu L et al (2010) HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207:2439–2453. doi: 10.1084/jem.20100587
16. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. doi: 10.1038/nature01322
17. Dang Y, Wagner WM, Gad E et al (2012) Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immune suppressive cells. Clin Cancer Res 18:3122–3131. doi: 10.1158/1078-0432.CCR-12-0113
18. De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23:277–286. doi: 10.1016/j.ccr.2013.02.013
19. De Santa F, Totaro MG, Prosperini E et al (2007) The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130:1083–1094. doi: 10.1016/j.cell.2007.08.019
20. DeNardo DG, Barreto JB, Andreu P et al (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102. doi: 10.1016/j.ccr.2009.06.018
21. Diaz-Montero CM, Salem ML, Nishimura MI et al (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59. doi: 10.1007/s00262-008-0523-4
22. Ebihara T, Azuma M, Oshiumi H et al (2010) Identification of a polyI: C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med 207:2675–2687. doi: 10.1084/jem.20091573
23. Ehrchen JM, Sunderkötter C, Foell D (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86:557–566. doi: 10.1189/jlb.1008647
24. Eriksson F, Tsagozis P, Lundberg K et al (2009) Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J Immunol 182(5):3105–3111. doi: 10.4049/jimmunol.0800224
25. Foster SL, Hargreaves DC, Medzhitov R (2007) Gene-specific control of inflammation by TLR induced chromatin modifications. Nature 447:972–978. doi: 10.1038/nature05836
26. Frede S, Stockmann C, Freitag P, Fandrey J (2006) Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J 396(3):517–527. doi: 10.1042/BJ20051839
27. Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33:949–955. doi: 10.1093/carcin/bgs123
28. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941–952. doi: 10.1038/nri1498
29. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi: 10.1038/nri2506
30. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268. doi: 10.1038/nri3175
31. Galdiero MR, Bonavita E, Barajon I et al (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218:1402–1410. doi: 10.1016/j.imbio.2013.06.003
32. Galluzzi L, Vacchelli E, Eggermont A et al (2012) Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 1:699–716. doi: 10.4161/onci.20696
33. Germano G, Frapolli R, Belgiovine C et al (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23:249–262. doi: 10.1016/j.ccr.2013.01.008
34. Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71:2411–2416. doi: 10.1158/0008-5472.CAN-10-2583
35. Guiducci C, Vicari AP, Sangaletti S et al (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65:3437–3446.
36. doi: 10.1158/0008-5472.CAN-04-4262
37. Hagemann T, Lawrence T, McNeish I et al (2008) “Re-educating” tumor-associated macrophages by targeting NF-kappa B. J Exp Med 205:1261–1268. doi: 10.1084/jem.20080108
38. Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322. doi: 10.1016/j.ccr.2012.02.022
39. Hanahan D, Weinberg RA (2010) Hallmarks of cancer: the next generation. Cell 144:646–674. doi: 10.1016/j.cell.2011.02.013
40. Hanson EM, Clements VK, Sinha P et al (2009) Myeloid-derived suppressor cells down-regulateL-selectin expression on CD4+ and CD8+T cells. J Immunol 183:937–944. doi: 10.4049/jimmunol.0804253
41. Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8:1369–1375. doi: 10.1038/ncb1507
42. Hiratsuka S, Watanabe A, Sakurai Y et al (2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10:1349–1355. doi: 10.1038/ncb1794
43. Honda K, Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:644–658. doi: 10.1038/nri1900
44. Hu X, Chen J, Wang L, Ivashkiv LB (2007) Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 82:237–243. doi: 10.1189/jlb.1206763
45. Huang B, Pan P-Y, Li Q et al (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131. doi: 10.1158/0008-5472.CAN-05-1299
46. Huang B, Lei Z, Zhao J et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86–92. doi: 10.1016/j.canlet.2006.12.012
47. Huang B, Zhao J, Unkeless JC et al (2008) TLR signaling by tumor and immune cells: a doubleedged sword. Oncogene 27:218–224. doi: 10.1038/sj.onc.1210904
48. Ishii M, Wen H, Corsa CAS et al (2009) Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114:3244–3254. doi: 10.1182/blood-2009-04-217620
49. Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327:291–295. doi: 10.1126/science.1183021
50. Jinushi M, Yagita H, Yoshiyama H, Tahara H (2013) Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends Mol Med 19:536–545. doi: 10.1016/j.molmed.2013.06.001
51. Kaczanowska S, Joseph AM, Davila E (2013) TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol 93:847–863. doi: 10.1189/jlb.1012501
52. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637–650. doi: 10.1016/j.immuni.2011.05.006
53. Khazaie K, Blatner NR, Khan MW et al (2011) The significant role of mast cells in cancer. Cancer Metastasis Rev 30:45–60. doi: 10.1007/s10555-011-9286
54. Kim S, Takahashi H, Lin W-W et al (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102–106. doi: 10.1038/nature07623
55. Kortylewski M, Kujawski M, Wang T et al (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314–1321. doi: 10.1038/nm1325
56. Krausgruber T, Blazek K, Smallie T et al (2011) IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12:231–238. doi: 10.1038/ni.1990
57. Lawrence T, Natoli G (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11:750–761. doi: 10.1038/nri3088
58. Lee C-H, Wu C-L, Shiau A-L (2010) Toll-like receptor 4 signaling promotes tumor growth. J Immunother 33:73–82. doi: 10.1097/CJI.0b013e3181b7a0a4
59. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612. doi: 10.1158/0008-5472.CAN-05-4005
60. Li H, Han Y, Guo Q et al (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182:240–249
61. Lin EY, Pollard JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. doi: 10.1158/0008-5472.CAN-07-0912
62. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–739. doi: 10.1084/jem.193.6.727
63. Liu C-Y, Xu J-Y, Shi X-Y et al (2013) M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 93:844–854. doi: 10.1038/labinvest.2013.69
64. Lu T, Ramakrishnan R, Altiok S et al (2011) Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 121:4015–4029. doi: 10.1172/JCI45862
65. Ma J, Liu L, Che G et al (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112. doi: 10.1186/1471-2407-10-112
66. Ma G, Pan P-Y, Eisenstein S et al (2011) Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity 34:385–395. doi: 10.1016/j.immuni.2011.02.004
67. Mantovani A, Sozzani S, Locati M et al (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555
68. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi: 10.1038/nature07205
69. Marigo I, Dolcetti L, Serafi ni P et al (2008) Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162–179. doi: 10.1111/j.1600-065X.2008.00602
70. Markiewski MM, DeAngelis RA, Benencia F et al (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9:1225–1235. doi: 10.1038/ni.1655
71. Mazzieri R, Pucci F, Moi D et al (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19:512–526. doi: 10.1016/j.ccr.2011.02.005
72. McCartney S, Vermi W, Gilfillan S et al (2009) Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 206:2967–2976. doi: 10.1084/jem.20091181
73. Movahedi K, Guilliams M, Van den Bossche J et al (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233–4244. doi: 10.1182/blood-2007-07-099226
74. Munn DH, Mellor AL (2004) IDO and tolerance to tumors. Trends Mol Med 10:15–18
75. Nagaraj S, Gupta K, Pisarev V et al (2007) Altered recognition of antigen is a mechanism of CD8+T cell tolerance in cancer. Nat Med 13:828–835. doi: 10.1038/nm1609
76. Nausch N, Galani IE, Schlecker E, Cerwenka A (2008) Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells. Blood 112:4080–4089. doi: 10.1182/blood-2008-03-143776
77. Nefedova Y, Nagaraj S, Rosenbauer A et al (2005) Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65:9525–9535. doi: 10.1158/0008-5472.CAN-05-0529
78. Newman KC, Riley EM (2007) Whatever turns you on: accessory-cell-dependent activation of NKcells by pathogens. Nat Rev Immunol 7:279–291. doi: 10.1038/nri2057
79. Oshiumi H, Matsumoto M, Funami K et al (2003) TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 4:161–167.doi: 10.1038/ni886
80. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506. doi: 10.4049/jimmunol.0802740
81. H. Shime et al. Peng J, Tsang JYS, Li D et al (2013) Inhibition of TGF-β signaling in combination with TLR7 ligation re-programs a tumoricidal phenotype in tumor-associated macrophages. Cancer Lett 331:239–249. doi: 10.1016/j.canlet.2013.01.001
82. Peranzoni E, Zilio S, Marigo I et al (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22:238–244. doi: 10.1016/j.coi.2010.01.021
83. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51. doi: 10.1016/j.cell.2010.03.014
84. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437. doi: 10.1038/nm.3394
85. Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124–127. doi: 10.1126/science.1140488
86. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9:57–63
87. Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177. doi: 10.1186/1479-5876-9-177
88. Sade-Feldman M, Kanterman J, Ish-Shalom E et al (2013) Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38:541–554. doi: 10.1016/j.immuni.2013.02.007
89. Satoh T, Takeuchi O, Vandenbon A et al (2010) The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 11:936–944. doi: 10.1038/ni.1920
90. Sawanobori Y, Ueha S, Kurachi M et al (2008) Chemokine-mediated rapid turnover of myeloidderived suppressor cells in tumor-bearing mice. Blood 111:5457–5466. doi: 10.1182/blood-2008-01-136895
91. Schmid MC, Avraamides CJ, Dippold HC et al (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19:715–727. doi: 10.1016/j.ccr.2011.04.016
92. Serafi ni P, Mgebroff S, Noonan K, Borrello I (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439–5449. doi: 10.1158/0008-5472.CAN-07-6621
93. Seya T, Shime H, Ebihara T et al (2010) Pattern recognition receptors of innate immunity and their application to tumor immunotherapy. Cancer Sci 101:313–320.doi: 10.1111/j.1349-7006.2009.01442
94. Seya T, Shime H, Matsumoto M (2012) TAMable tumor-associated macrophages in response to innate RNA sensing. Oncoimmunology 1:1000–1001. doi: 10.4161/onci.19894
95. Sfondrini L, Rossini A, Besusso D et al (2006) Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 176:6624–6630
96. Shime H, Matsumoto M, Oshiumi H et al (2012) Toll-like receptor 3 signaling converts tumor supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A 109:2066–2071. doi: 10.1073/pnas.1113099109
97. Shime H, Kojima A, Maruyama A et al (2014) Myeloid-derived suppressor cells confer tumor suppressive functions on natural killer cells via polyinosinic: polycytidylic acid treatment in mouse tumor models. J Innate Immun 6:293–305. doi: 10.1159/000355126
98. Shirota Y, Shirota H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188:1592–1599. doi: 10.4049/jimmunol.1101304
99. Shojaei F, Wu X, Zhong C et al (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450:825–831. doi: 10.1038/nature06348
100. Shojaei F, Zhong C, Wu X et al (2008) Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18:372–378. doi: 10.1016/j.tcb.2008.06.003
101. Sica A (2010) Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 32:153–158
102. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795. doi: 10.1172/JCI59643
103. Sinha P, Okoro C, Foell D et al (2008) Pro inflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666–4675. doi: 10.4049/jimmunol.181.7.4666
104. Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86:1065–1073. doi: 10.1189/jlb.0609385
105. Sonda N, Chioda M, Zilio S et al (2011) Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol 23:279–285. doi: 10.1016/j.coi.2010.12.006
106. Spence S, Fitzsimons A, Boyd CR et al (2013) Suppressors of cytokine signaling 2 and 3 diametrically control macrophage polarization. Immunity 38:66–78. doi: 10.1016/j.immuni.2012.09.013
107. Srikrishna G (2011) S100A8 and S100A9: new insights into their roles in malignancy. J InnateImmun 4:31–40. doi: 10.1159/000330095
108. Srivastava MK, Sinha P, Clements VK et al (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68–77. doi: 10.1158/0008-5472.CAN-09-2587
109. Srivastava MK, Zhu L, Harris-White M et al (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 7:e40677. doi: 10.1371/journal.pone.0040677
110. Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classicHodgkin’s lymphoma. N Engl J Med 362:875–885. doi: 10.1056/NEJMoa0905680
111. Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13:739–752. doi: 10.1038/nrc3581
112. Toshchakov V, Jones BW, Perera P-Y et al (2002) TLR4, but not TLR2, mediates IFN-β–inducedSTAT1α/β-dependent gene expression in macrophages. Nat Immunol 3:392–398. doi: 10.1038/ni774
113. Ugel S, Delpozzo F, Desantis G et al (2009) Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9:470–481. doi: 10.1016/j.coph.2009.06.014
114. Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237–251. doi: 10.1038/nrc3237
115. Vasquez-Dunddel D, Pan F, Zeng Q et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123:1580–1589. doi: 10.1172/JCI60083
116. Waight JD, Netherby C, Hensen ML et al (2013) Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 123:4464–4478. doi: 10.1172/JCI68189
117. Wang R-F, Miyahara Y, Wang HY (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27:181–189. doi: 10.1038/sj.onc.1210906
118. Wang Y-C, He F, Feng F et al (2010) Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70:4840–4849. doi: 10.1158/0008-5472.CAN-10-0269
119. Xu H, Zhu J, Smith S et al (2012) Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol 13:642–650. doi: 10.1038/ni.2304
120. Yamamoto M, Sato S, Hemmi H et al (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:640–643. doi: 10.1126/science.1087262
121. Yang W-C, Ma G, Chen S-H, Pan P-Y (2013) Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol 5:207–209. doi: 10.1093/jmcb/mjt009
122. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791–5802
123. Youn J-I, Kumar V, Collazo M et al (2013) Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 14:211–220. doi: 10.1038/ni.2526
124. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51. doi: 10.1038/nri1995
125. Zea AH, Rodriguez PC, Atkins MB et al (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044–3048. doi: 10.1158/0008-5472.CAN-04-4505
126. Zhao X, Mohaupt M, Jiang J et al (2007) Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res 67:4443–4450. doi: 10.1158/0008-5472.CAN-07-0185
127. Zhao X, Rong L, Zhao X et al (2012) TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 122:4094–4104. doi: 10.1172/JCI64115
128. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727. doi: 10.1038/nri1936
129. Zoglmeier C, Bauer H, Nörenberg D et al (2011) CpG blocks immunosuppression by myeloidderived suppressor cells in tumor-bearing mice. Clin Cancer Res 17:1765–1775. doi: 10.1158/1078-0432.CCR-10-2672